Azithromycin News and Research

RSS

Azithromycin, also known as Zithromax, belongs to the class of medicines known as antibacterials orantibiotics. These medicines kill bacteria (small organisms that can cause infection in humans) or stopbacteria from growing. Patients with weakened immune systems, includingpeople with HIV, tend to have more frequent andmore serious bacterial infections. Azithromycinwas approved by the FDA on June 14, 1996, formany uses, including the prevention and treatmentof Mycobacterium avium complex (MAC) inpersons with advanced HIV infection. It is alsobeing investigated to see how well it works inpreventing other kinds of bacterial infections inpeople with HIV.

Investigators map how drugs were used on people hospitalized with COVID-19 infection

A record of medicine utilization patterns assembled by an interdisciplinary team of researchers at the University of California, Irvine and the UC San Diego School of Medicine reveals the thought, care and scientific rigor clinicians at UC Health medical centers applied in their treatment of patients with COVID-19 in 2020.

21 May 2021

Ravi Sheth receives 2020 Hertz thesis prize for transforming microbial research

Hertz Fellow Ravi Sheth says his lab in the Brooklyn Navy Yard is "like a Willy Wonka factory of microbes" geared toward improving the taste and safety of food and beverages.

4 May 2021

Phase 3 trial finds corticosteroid inhaler speeds recovery time in COVID-19 patients

The corticosteroid budesonide shows promise in treating patients with mild COVID-19 infection. Interim analysis of the phase 3 PRINCIPLE clinical trial was posted to the medRxiv preprint server. Researchers found a 3-day faster recovery of COVID-19 symptoms in people at high risk for severe side effects administered a budesonide inhaler. There was also a 2.1% reduction in hospitalization and death.

14 Apr 2021

Hydroxychloroquine has no effect in treating people with COVID-19, study shows

A year ago, infectious disease doctor Christine Johnston was leading a study on the use of hydroxychloroquine for the treatment of people with COVID-19.

10 Mar 2021

Five herbal medicines show potent activity against Babesia duncani in the lab

Bay Area Lyme Foundation, a leading sponsor of Lyme disease research in the U.S., today announced the publication of new data finding that five herbal medicines had potent activity compared to commonly-used antibiotics in test tubes against Babesia duncani, a malaria-like parasite found on the West Coast of the U.S. that causes the disease babesiosis.

9 Mar 2021

Study calls for continuous monitoring of dark web marketplaces in view of vaccines shortage

New research carried out by City data scientist, Dr. Andrea Baronchelli, and colleagues, into the dark web marketplace (DWM) trade in products related to COVID-19, has revealed the need for the continuous monitoring of dark web marketplaces (DWMs), especially in light of the current shortage and availability of coronavirus vaccines.

5 Feb 2021

Ivermectin may not be the ‘silver bullet’ antiviral against COVID-19

A team of researchers based in Peru and the U.S. recently examined the role of the anti-parasitic drug ivermectin in treating COVID-19.

1 Feb 2021

Study shows that single water molecule may cause antibiotic resistance

New high-resolution structures of the bacterial ribosome determined by researchers at the University of Illinois Chicago show that a single water molecule may be the cause -; and possible solution -; of antibiotic resistance.

20 Jan 2021

Are antibiotic regimens for critical COVID-19 patients with bacterial superinfection unnecessarily high?

A new study by researchers at Northwestern University Feinberg School of Medicine, USA, shows that antibiotic regimens for critically ill COVID-19 patients with bacterial superinfections may be promoting an unnecessarily high.

19 Jan 2021

Azithromycin trial fails to provide evidence of benefit in COVID-19

Early on in the COVID-19 pandemic, azithromycin was regarded as being a potentially highly effective drug against the virus that causes it, SARS-CoV-2.

16 Dec 2020

Remdesivir likely to be highly effective treatment for COVID-19

The drug remdesivir is likely to be a highly effective antiviral against SARS-CoV-2, according to a new study by a team of UK scientists.

14 Dec 2020

Researchers use AI platform to identify best combination of available therapies against COVID-19.

A team of researchers from the National University of Singapore (NUS) has utilized a ground-breaking artificial intelligence (AI) platform to derive an optimal combination of available therapies against SARS-CoV-2, the cause of COVID-19.

11 Dec 2020

Using AI to find optimal combination of available therapies against SARS-CoV-2

A team of researchers from the National University of Singapore has utilized a ground-breaking artificial intelligence (AI) platform to derive an optimal combination of available therapies against SARS-CoV-2, the cause of COVID-19.

10 Dec 2020

Chloroquine/hydroxychloroquine could treat COVID-19 infection

The recent serious outbreak of Covid19 has affected (November 13, 2020) 53,796,098 people worldwide, resulting in 37,555,669 recovered, 1,310,250 deaths, and a large number of open cases.

1 Dec 2020

Excessive use of antibiotics during COVID-19 pandemic could intensify drug resistance

A new study published in the journal Science of The Total Environment in November 2020 discusses this potentially serious issue along with its wider consequences.

30 Nov 2020

Steam inhalation therapy found to inactivate SARS-CoV-2 virions

Researchers have published a study on the efficacy of steam inhalations as another possible treatment to help mitigate SARS-CoV-2 infection.

30 Nov 2020

Scientists investigate how cell membrane and COVID-19 virus impact each other

The cell membrane is the cell's outermost line of defense against SARS-CoV-2, the novel coronavirus responsible for COVID-19 disease.

20 Nov 2020

Drugs targeting neutrophils could reduce ARDS in severe COVID-19

Scientists in Taiwan recently published a report on their use of anti-neutrophil strategies to treat acute respiratory distress syndrome (ARDS) – a life-threatening condition that can arise in critical COVID-19 cases – in the journal Frontiers in Pediatrics.

15 Nov 2020

Aspirin to be tested as a potential COVID-19 treatment as part of RECOVERY trial

Now, in new research, the everyday painkiller aspirin will be evaluated as a potential treatment for COVID-19 in one of the United Kingdom’s most significant trials, aiming to evaluate whether it can reduce the risk of blood clots in infected people.

9 Nov 2020

Study suggests honey and Nigella sativa expedites viral clearance in COVID-19 patients

A team of researchers from various institutes across Pakistan, Chile, Canada, and the USA recently conducted a clinical trial to investigate the potential effectiveness of a combination of honey and Nigella sativa (HNS) in treating COVID-19 patients. Their study is published on the preprint server medRxiv prior to the scientific peer review process.

8 Nov 2020